Cerenome Inc(CNSY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 4 at 7:30 PM ET (Korea 9/5 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.41 | Insider Own | 0.99% | Shs Outstand | 7.6M | Perf Week | -9.67% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 45.38% | Insider Trans | - | Shs Float | 7.5M | Perf Month | -28.63% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.89 | Inst Own | 15.75% | Short Float | 8.32% | Perf Quarter | -49.08% |
| Income | -0.03B | P/S | 4.98 | EPS this Y | 39.52% | Inst Trans | 3.85% | Short Ratio | 4.64 | Perf Half Y | -61.83% |
| Sales | 0.00B | P/B | 3.69 | EPS next 5Y | 80.97% | ROA | -214.01% | Short Interest | 0.62M | Perf YTD | -78.49% |
| Book/sh | 0.75 | P/C | 2.43 | EPS past 3/5Y | 70.82% 59.95% | ROE | -614.05% | 52W High | -88.24% ($23.42) | Perf Year | -75.49% |
| Cash/sh | 1.13 | P/FCF | - | Sales past 3/5Y | 185.5% 76.66% | ROIC | -477.54% | 52W Low | 5.19% ($2.62) | Perf 3Y | -96.06% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 91.97% | Gross Margin | 89.58% | Volatility(W/M) | 7.51% 6.93% | Perf 5Y | -99.63% |
| Dividend TTM | - | EV/Sales | 2.94 | Sales Y/Y TTM | -20.95% | Oper. Margin | -628.12% | ATR (14) | 0.24 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | EPS Q/Q | -701.84% | Profit Margin | -620.7% | RSI (14) | 34.7 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.35 | Sales Q/Q | -70.43% | SMA20 | -13.51% ($3.19) | Beta | 1.43 | Target Price | $53.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/14 | SMA50 | -24.13% ($3.64) | Rel Volume | 0.25 | Prev Close | $2.98 |
| Employees | 28 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -48.86% -63.08% | SMA200 | -60.95% ($7.07) | Avg Volume(3M) | 0.13M | Price | $2.76 |
| IPO | 2003/10/22 | Option/Short | No/Yes | Trades | 403 | Volume | 33,838 | Change | -7.55% |
Company
CNSY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US biotech company that focuses on both diagnosing and developing targeted therapies for central nervous system cancers. The business is built around a core strategy of combining a commercial diagnostic test that analyzes cerebrospinal fluid, a radiotherapeutic candidate, and a data analytics partnership to concentrate on the central nervous system oncology field. The company has refreshed its brand identity by adopting a new name and ticker symbol to better reflect its business focus.
Over the past 1 year, on the lower side
88% below its 1-year high.
CNSY has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.5% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -96.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 15.8%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $21M.
CNSY $21M PER -
VRTX $138B PER 31.8
REGN $85B PER 20.5
ARGX $65B PER 39.4
FAQ
What kind of company is CNSY?
CNSY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CNSY?
The market cap of CNSY is approximately $21M, ranking 5,287 within its sector.
What is the 52-week high and low for CNSY?
CNSY has recorded a 52-week high of $23.42 and a low of $2.62.
